Carlsbad, CA. – April 16, 2015 – Applied Spectral Imaging (ASI, www.spectral-imaging.com) announced today that it has received clearance from the South Korean Ministry of Food and Drug Safety (MFDS) for its GenASIs HiPath image capture and...

With almost 1 million new cases per year, gastric cancer is currently the number four most common malignant disease. Today, there is no universal standard treatment. Recently, however, the ToGA trial demonstrated efficacy of Trastuzumab...

Three Events - One Product Family! Join Applied Spectral Imaging at the following events in March to learn about ASI’s GenASIs Platform. Accurate. Standardized. Immediate USCAP 2015 - United States & Canadian Academy of...

After thorough testing, and internal clinical validation, Herlev University Hospital selects Visiopharm’s ONCOtopix™ Dx – a platform for computer assisted quantitative diagnostic immunohistochemistry (IHC) and In-Situ Hybridization...

Carlsbad, CA. - January 21, 2015 - Applied Spectral Imaging (ASI, www.spectral-imaging.com) announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its GenASIs HiPath image capture and analysis...

Come meet Visiopharm August 30th - September 3rd in London, UK at the 26th European Congress of Pathology. Learn about our leading image analysis Quantitative Digital Pathology solutions for research and cancer diagnostics; utilizing our...